Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

September 23, 2026 Marina Temkin

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

Previous Article
VC firm Bessemer now has another $5.75B to invest in (what else?) AI
VC firm Bessemer now has another $5.75B to invest in (what else?) AI

The VC firm says that AI-native companies are growing faster than any technology, ever.

Next Article
Modal Motors is trying to cut China out of electric motors entirely
Modal Motors is trying to cut China out of electric motors entirely

The startup is working on small, light motors with no rare-earth magnets that are suited for drones, fans, ...